Purpose of review: Year 2013 has been rich in presentations and publications about new emerging anticancer agents, both in peer-review journals and in international meetings such as American Society of Clinical Oncology (ASCO), European Cancer Congress (European Cancer Organization - ECCO/European Society of Medical Oncology - ESMO), American Association for Cancer Research Meeting (AACR), Molecular Target and Cancer Therapeutics AACR-NCI-EORTC International Conference and Targeted Anticancer Therapies Meeting (TAT). Our purpose is to give an update in 2013's most important advances in new anticancer therapies.
Recent findings: We will highlight recent advances in immunotherapy; combinations of targeted agents to overcome resistance; second and third generation of targeted agents against oncogene addiction and new antibody-drug conjugates against epithelial tumors.
Summary: Future implications of this year's emerging therapies will probably lead to the approval of new immunotherapies for treatment of several tumor types and second-generation agents to overcome resistance in those tumors with oncogene addiction.